Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06462508
Overview
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[68Ga\]Ga-PSMA-11.
Help us improve your experience